J.L. Bainbridge & Co’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$74M Buy
61,737
+283
+0.5% +$289K 5.83% 6
2026
Q1
$56.5M Buy
61,454
+6
+0% +$6.08K 5.03% 7
2025
Q4
$66M Sell
61,448
-334
-0.5% -$319K 5.33% 5
2025
Q3
$47.1M Buy
61,782
+61,258
+11,690% +$45.6M 3.93% 9
2025
Q2
$408K Buy
524
+1
+0.2% +$777 0.04% 61
2025
Q1
$432K Hold
523
0.04% 58
2024
Q4
$404K Sell
523
-2,907
-85% -$2.41M 0.04% 64
2024
Q3
$3.04M Hold
3,430
0.29% 29
2024
Q2
$3.11M Hold
3,430
0.31% 29
2024
Q1
$2.67M Buy
3,430
+1
+0% +$712 0.28% 27
2023
Q4
$2M Buy
3,429
+2,912
+563% +$1.7M 0.24% 29
2023
Q3
$277K Sell
517
-29
-5% -$14.9K 0.04% 60
2023
Q2
$256K Buy
+546
New +$229K 0.03% 61

Other funds holding LLY

J.L. Bainbridge & Co's LLY Position: Q2 2026 in Review

J.L. Bainbridge & Co increased its Eli Lilly (LLY) stake by 0.46% in Q2 2026, buying an estimated $289K and bringing the position to 61,737 shares worth $74M. The position accounts for 5.83% of the portfolio, ranked #6.

J.L. Bainbridge & Co first reported a position in LLY in Q2 2023 and has held it in 13 quarters since. 2,247 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • J.L. Bainbridge & Co held 61,737 shares of Eli Lilly worth $74M as of Q2 2026.
  • J.L. Bainbridge & Co bought 283 Eli Lilly shares in Q2 2026, an estimated $289K.
  • Eli Lilly made up 5.83% of J.L. Bainbridge & Co's portfolio in Q2 2026, its #6 holding.
  • J.L. Bainbridge & Co first reported a position in Eli Lilly in Q2 2023 and has held it in 13 quarters since.
  • 2,247 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on J.L. Bainbridge & Co's 13F filing for Q2 2026, filed 22 Jul 2026.